Novartis
Current and novel options in CML therapy - how to optimize treatment
outcomes of chronic myeloid leukemia without comprromises?

Abbvie
Let`s discuss lymphoid malignancies: An interactive symposium on therapy
management in Swiss clinical practice in CLL and DLBCL

Astellas
Exploring a new treatment option for nmHSPC patients with high risk BCR

Eli Lilly
The importance of risk assessment in early high risk Breast Cancer:
MONARCH E from trial design, risk assessment to patient outcome 

GSK
Myelofibrosis in Routine Clinical Practice: How do I manage patients?'

AstraZeneca
Navigating the complexity of cancer treatment: the opportunity of
shared-decision making in light of the evolving treatment landscape

 Johnson & Johnson
Line after line: treatment of multiple myeloma – a changing
landscape (working title; subject to change)

Servier
Recent advances and future directions of IDH mutant inhibition in cancer therapy